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Abstract
Thyroid adenomas are common benign human tumors with a high prevalence of about 5% of the adult population even in
iodine sufficient areas. Rearrangements of chromosomal band 19q13.4 represent a frequent clonal cytogenetic deviation in
these tumors making them the most frequent non-random chromosomal translocations in human epithelial tumors at all.
Two microRNA (miRNA) gene clusters i.e. C19MC and miR-371-3 are located in close proximity to the breakpoint region of
these chromosomal rearrangements and have been checked for a possible up-regulation due to the genomic alteration. In
4/5 cell lines established from thyroid adenomas with 19q13.4 rearrangements and 5/5 primary adenomas with that type of
rearrangement both the C19MC and miR-371-3 cluster were found to be significantly overexpressed compared to controls
lacking that particular chromosome abnormality. In the remaining cell line qRT-PCR revealed overexpression of members of
the miR-371-3 cluster only which might be due to a deletion accompanying the chromosomal rearrangement in that case.
In depth molecular characterization of the breakpoint in a cell line from one adenoma of this type reveals the existence of
large Pol-II mRNA fragments as the most likely source of up-regulation of the C19MC cluster. The up-regulation of the
clusters is likely to be causally associated with the pathogenesis of the corresponding tumors. Of note, the expression of
miRNAs miR-520c and miR-373 is known to characterize stem cells and in terms of molecular oncology has been implicated
in invasive growth of epithelial cells in vitro and in vivo thus allowing to delineate a distinct molecular subtype of thyroid
adenomas. Besides thyroid adenomas rearrangements of 19q13.4 are frequently found in other human neoplasias as well,
suggesting that activation of both clusters might be a more general phenomenon in human neoplasias.
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Introduction
Thyroid adenomas are highly frequent human tumors that can
be distinguished from their malignant counterparts i.e. follicular
carcinomas by an encapsulated growth and a lack of invasiveness,
respectively. Even in iodine sufficient areas thyroid adenomas
occur in 4–7% of adults and in iodine deficient areas this number
can rise to about 50%. The pathogenesis of these frequent benign
tumors is only poorly understood but clonal chromosomal
aberrations can be observed in roughly 40% of the nodules and
are likely to pinpoint genomic regions and genes relevant for the
development of the disease [1]. About 20% of the tumors with
clonal cytogenetic aberrations show abnormalities involving
chromosomal band 19q13 [2]. Given the extremely high
prevalence of thyroid adenomas in Europe and the U.S. alone
four to five million people can be estimated to be affected by this
genomic alteration in their thyroid. So far, by positional cloning
and in silico analyses the breakpoints have been found to cluster
within a segment of 150 kb (kilobases) [3] that is located in close
proximity to the genes encoding two miRNA clusters i.e. C19MC
and miR-371-3 (Figure 1). The 100 kb long C19MC cluster with
46 tandemly repeated, primate-specific miRNA genes accounts for
about 8% of all known human miRNA genes making it the largest
human miRNA gene cluster discovered to date [4]. Ren et al. [5]
have predicted 4,691 targets for this cluster. Recent evidence
suggests that its miRNAs are encoded by an intron of a non-
protein coding Pol-II transcript which is mainly expressed in the
placenta [4]. In contrast to that large cluster the miR-371-3 cluster
is much smaller spanning a region of approximately 1,050 bp
where five miRNAs are encoded. The miRNAs of both clusters
belong to a large miRNA family sharing a similar seed sequence
[6]. Of note, several groups recently have linked the expression of
members of the C19MC as well as the miR-371-3 cluster with the
miRNA signature characteristic for human embryonic stem cells
(hESC) [5,6,7]. First evidence for an oncogenic potential of miR-
373 has been obtained in human testicular germ cell tumors where
it was shown to allow tumorigenic growth in the presence of wild-
type p53 [8]. In prostate cancer both miR-373 and miR-520c
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invasion in vitro [9]. Recently, Huang et al. [10] were able to
demonstrate that miR-373 and miR-520c promote tumor invasion
and metastasis in vivo and in vitro by the suppression of CD44.
Interestingly, qualitative and quantitative changes of CD44
expression have been implicated in the growth and progression
of thyroid tumors. Because invasive behavior is of pivotal
significance in the differential diagnosis of thyroid tumors we
have addressed this study on a possible up-regulation of both
miRNA clusters in thyroid adenomas.
Results
Cell Lines from Thyroid Adenomas with 19q13-
Rearrangement Show Upregulated Expression of miRNAs
of the C19MC Cluster
To evaluate the role of either of the two miRNA clusters located
in close proximity to the breakpoint region as possible targets of
the 19q13 translocations in thyroid adenomas, we have first used
RT-PCR to compare the expression of three members of the
C19MC cluster, i.e. miR-512-5p, miR-517a, and miR-519a in five
cell lines established from thyroid adenomas with 19q13
rearrangements and three cell lines from adenomas with other
clonal abnormalities (Table 1). All cell lines had been established
from primary tumors by using a SV40 derived subgenomic
fragment. The three miRNAs chosen were spread over the whole
cluster and served as examples for the more than 46 different but
similar cluster members. Four of the five cell lines with 19q13
rearrangements expressed detectable levels of the three miRNAs
whereas in the remaining cell line (S121, Table 1) and all cell lines
with other aberrations no expression of any of the three miRNAs
was noted (Figure 2).
We have then used these cell lines to quantify the expression of
another member of the C19MC cluster i.e. miR-520c by real-time
PCR (qRT-PCR). Akin to the results obtained for the other
members of that cluster high expression was noted only in the
same four cell lines with 19q13 rearrangements expressing miR-
512-5p, miR-517a, and miR-519a (Figure 3a) whereas a
significantly lower expression was seen in the remaining cell lines
(p=0.001659; for details see Table 2). Most likely, the exception-
ally low expression of all examined members of the C19MC
cluster in cell line S121 may result from a deletion of that part of
the breakpoint region resulting from the chromosomal transloca-
tion the breakpoint of which had previously been mapped at a
Figure 1. Scheme of the chromosomal region 19q13.4 with the two miRNA clusters C19MC and miR-371-3. Protein coding genes are
represented by gray bars whereas genes of miRNA clusters are given as blue (C19MC cluster) and green (miR-371-3 cluster) lines, respectively. The
common breakpoint cluster (BPC) of benign thyroid tumors of about 150 kb is indicated by a vertical arrow. miR-512-1 (pre-miR) is coding for mature-
miR-512-5p, miR-371 (pre-miR) is coding for mature-miR371-3p. Gene symbols refer to the following protein coding genes: ZNF331 = zinc finger
protein 331, DPRX = divergent-paired related homeobox, NLRP12 = NLR family, pyrin domain containing 12.
doi:10.1371/journal.pone.0009485.g001
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all cell lines with breakpoints upstream of the C19MC cluster
evidence for an upregulation of four cluster members was
obtained. Because of a common regulation of that cluster, no
further members were examined.
Thyroid Adenomas with 19q13 Rearrangements Show
Upregulation of miRNAs of the C19MC Cluster and the
miR-371-73 Cluster
To see if comparable results can be obtained for primary tumors
as well we have characterized 70 thyroid nodules by interphase
Table 1. Used tissue samples and cell lines.
sample no. thyroid material cytogenetic subtype/FISH karyotype
S40.2* cell line 46,XX,t(1;19)(p35 or p36;q13)[19]
S121* cell line 46,XX,t(5;19)(q13;q13)[52]
S141.2* cell line 46,XX,t(2;19)(p12 or p13;q13)[59]
S211
# cell line 46,XX,inv(4)(p15.2q12),t(5;19)(p14 or 15.1;q13),t(9;18)(q12;q22)[25]
S270.2 cell line 46,XX,t(2;3)(q21;q27 or q28)[13]
S290.1 cell line 46,XX,t(11;19)(q23;q13)[19]
S325
p cell line 46,XX,t(2;20;3)(p21;q11.2;p25)[17]
S533
p cell line 46,XX,t(2;7)(p21;p15)[16]
S805 adenoma 46,XX
S806 adenoma 46,XX
S889 adenoma 46,XX
S920 adenoma 46,XX
S925 adenoma 46,XX
S801 adenoma 46,XY,t(2;4),t(2;14;19)
nuc ish(59-tbpc19,39-tbpc19)x2(59-tbpc19 sep 39-tbpc19x1)
S814 adenoma 46,XX,del(6)(q21,22)
nuc ish(59-tbpc19,39-tbpc19)x2(59-tbpc19 sep 39-tbpc19x1)
S842 adenoma 46,XX,t(1;19)(q32;q13)[8]/46,XX[24]
nuc ish(59-tbpc19,39-tbpc19)x2(59-tbpc19 sep 39-tbpc19x1)
S846 adenoma 46,XY
nuc ish(59-tbpc19,39-tbpc19)x2(59-tbpc19 sep 39-tbpc19x1)
S849 adenoma not evaluable by cc
nuc ish(59-tbpc19,39-tbpc19)x2(59-tbpc19 sep 39-tbpc19x1)
Cytogenetic details of the analyzed samples from follicular thyroid tumors and the cell lines used with their genetic subgroups determined by conventional
cytogenetics and/or by interphase fluorescence in situ hybridization (I-FISH) with break-apart, dual-color rearrangement probe (tbpc-19). In case of the cell lines only the
clonal aberrations found in the original tumors the cell lines have been established from are given.
Ref.: (*) [30]; (#)[ 2 ] ;( p) [31].
doi:10.1371/journal.pone.0009485.t001
Figure 2. Expression analysis of miR-517a by RT-PCR. PCR reactions were performed and then analyzed in 4% small DNA Agarose. The
expected DNA-fragment has a size of 62 bp, Ultra low range Ladder (Fermentas) was used as Marker (M). Lane 1: S40.2, 2: S40.2 without reverse
transcriptase (–RT), 3: S121, 4: S121–RT, 5: thyroid (normal), 6: thyroid–RT, 7: placenta, 8: placenta-RT, 9: S270.2, 10: S270.2–RT, 11: S290.1, 12: S290.1–
RT, 13: S141.2, 14: S325, 15: S211, 16: S211–RT, 17: fetal RNA, 18: adult testis, 19: fetal RNA-RT, 20: S141.2-RT, 21: adult testis-RT, 22: S325-RT (for details
of the cell lines and tumor samples see Table 1).
doi:10.1371/journal.pone.0009485.g002
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obtained prior to cell culturing. The results were usually
supplemented by conventional cytogenetics. FISH screening/
conventional cytogenetic analysis of the nodules detected five
tumors with clonal rearrangements of chromosomal band 19q13
(Figure 4). Akin to the cell lines semi-quantitative RT-PCR
revealed an upregulation of 3 miRNAs and again, as further
example of that cluster, results were supplemented with qRT-PCR
analyses for miR-520. We have shown that all thyroid adenomas
with 19q13 rearrangements express significantly higher levels
(p#0.003133) of miR-520 than samples without 19q13 rearrange-
ments (adenomas and surrounding thyroid tissue; for details see
Table 1) (Figure 3b).
To see if the 19q13 rearrangements also activate the expression
of the miR-371-3 cluster we have studied the expression of three
members of this cluster in the same samples used before. All
tumors with 19q13 rearrangements were shown to express
significantly higher levels of miR-371-3p, miR-372, and miR-
373 than three samples of surrounding histologically normal
thyroid tissue (p#0.02236) and the five cytogenetically normal
adenomas (p#0.01428) (Figure 3c). We then quantified the
expression of miR-371-3p, miR-372, and miR-373 in the cell
lines where comparable results were obtained (Figure 3d).
Interestingly, cell line S121 with absent or very low expression
of the C19MC cluster members showed a high expression of the
miR-371-3 cluster thus further strengthening the idea that in this
cell line part of the C19MC cluster is deleted.
In a Thyroid Adenoma Cell Line the C19MC Cluster
Becomes Part of a Pol-II Fusion mRNA
In order to further understand the mechanisms involved in the
activation of the miRNA clusters one cell line of the 19q13 group
has been investigated in more detail. This cell line shows a
rearrangement of chromosomal band 19q13.4 resulting from an
apparently balanced translocation t(1;19)(1p35.2;q13.4) (Figure 5).
By appropriate FISH analyses using BAC (bacterial artificial
chromosome) probes the breakpoint on chromosome 1 was
mapped within pumilio homolog 1 (PUM1) (Figure 6). PUM1 encodes
a RNA-binding protein and shows a widespread expression in
adult tissues. It has 22 exons and spans about 150 kb on
chromosomal band 1p35.2 [11,12]. To further characterize the
breakpoint region at the molecular level additional FISH studies
were performed allowing to narrow down the 1p35.2 breakpoint
to the 6,144 kbp intron 10 of PUM1. By the translocation the
Figure 3. Expression of miR-520c, miR-371-3p, miR-372 and miR-373 in cell lines and primary tumors. Relative expression of miRNAs
was determined by real-time PCR (mean s.d. from three independent experiments). Values of miRNA were normalized to RNU6B (RNA, U6 small
nuclear 2) (A) miR-520c expression in thyroid cell lines, five cell lines derived from adenomas with 19q13.4 rearrangements (S141.2, S290.1, S121,
S211, S40.2) (red bars) and three cell lines derived from thyroid adenomas with other structural rearrangements (S533, S325, S270.2) (light red bars).
(B) miR-520c expression in three samples of non-neoplastic thyroid tissues (Th1, Th2, Th3) (light red bars), five adenomas with 19q13.4 rearrangement
(S801, S849, S842, S846, S814) (red bars) and five adenomas without cytogenetically detectable aberrations (S805, S806, S889, S920, S925) (light red
bars). (C) miR-371-3 expression in three samples of non-neoplastic thyroid tissues (gray (miR-371-3p), light green (miR-372) and light blue (miR-373)),
five adenomas with 19q13.4 rearrangement (black (miR-371-3p), green (miR-372) and blue (miR-373)) and five adenomas without cytogenetically
detectable aberrations (gray, light green and light blue bars) (for case numbers refer to Table 1). (D) miR-371-3 expression in thyroid cell lines, five cell
lines derived from adenomas with 19q13.4 rearrangements (black (miR-371-3p), green (miR-372) and blue (miR-373)) and three cell lines derived from
thyroid adenomas with other structural rearrangements (gray (miR-371-3p), light green (miR-372) and light blue (miR-373)) (for case numbers refer to
Table 1).
doi:10.1371/journal.pone.0009485.g003
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juxtaposed to the miRNA clusters (Figure 7). In addition, we have
therefore used 39RACE-PCR to detect possible fusion transcripts
between the proximal part of PUM1 and sequences from
chromosome 19. Among several aberrant transcripts a fusion
transcript consisting of exon 1–10 of PUM1 followed by an ectopic
sequence of the chromosome 19 breakpoint region was detected
(Figure 8) and sequenced (Genbank Accession number
GQ334687). This transcript further confirms that the chromo-
somal break in this cell line is indeed located within intron 10 of
PUM1. Accordingly, we have performed RT-PCR experiments
using a sequence within exon 10 as the forward primer by which
we were able to detect part of one fusion transcript (Figure 8)
(Genbank Accession number GQ334688) with a border clearly
extending the distal border of C19MC (Figure 7). The 59 splice site
of intron 10 is not completely homologous to the consensus
sequence of human introns (Figure 9c)[13]. But the 39splice sites
on either site of the fusion are in line with the conserved consensus
sequence and a upstream region known as the polypyrimidine
tract (Figure 9a,b). However, from these results it seems reasonable
to assume that in the cell line S40.2 both clusters become part of
large Pol-II transcript driven by the PUM1 promoter. An in silico
analysis of intron 10 of PUM-1 as well as the chromosome 19
breakpoint region did not reveal obvious sequence homologies
pointing to homologous recombination as a mechanism underly-
ing the chromosomal rearrangement seen in that cell line.
Discussion
Specific structural chromosome abnormalities have turned out to be
valuable signposts indicating the position of protein-coding genes with
oncogenic potential. Recently, in addition some evidence for a causal
association of some chromosomal rearrangements with the activity of
microRNA coding genes has been presented [14,15,16]. Herein, we
were able to show that a highlyfrequent translocation in benignthyroid
tumors i.e. the 19q13.4 rearrangement targets and activates two
microRNA clusters in close proximity to the chromosomal breakpoint
cluster the expression of which is otherwise almost exclusively confined
to embryonic and fetal development. Activation by an ectopic Pol-II
promoter may generally be the mechanism by which the translocations
activate both miRNA clusters and fits with the apparent ‘‘natural’’
generation of the miRNAs of the C19MC cluster from a large Pol-II
driven transcript as witnessed by the results of a recent study [4]. From
the histologic analyses performed herein no evidence for invasiveness of
the corresponding tumors has been found that by definition would lead
to the diagnosis of a follicular carcinoma but this does not rule out a
higher risk of these tumors to become malignant. Generally, members
of both clusters have been implicated in malignant growth. In human
testicular germ cell tumors evidence for an oncogenic potential of miR-
373 has been obtained. In these tumors the expression of miR-373 was
shown to allow tumorigenic growth in the presence of wild-type p53
[8]. As another example in a recent paper hsa-miR-518c and hsa-miR-
373 were among the microRNAs associated with the tumorigenesis of
retinoblastomas [17]. In breast cancer, miR-373 and miR-520c
promote tumor invasion and metastasis in vivo and in vitro by the
suppression of CD44 [10]. Interestingly, the expression of a miRNA of
the C19MC cluster i.e. miR-516-3p recently has been linked to higher
aggressiveness of breast cancer as well. Based on a large-scale screen for
miRNA expression patterns associated with distant metastasis Foekens
et al. [17] were able to show that miR-516-3p belongs to four miRNAs
the expression of which is associated with an adverse prognosis in
estrogen receptor-positive, lymph node-negative primary breast cancer
[18]. Moreover, forced expression of miR-373 leads to a reduction in
the nucleotide excision repair (NER) protein, RAD23B, as well as in
RAD52 [19] thereby possibly contributing to a higher genome
instability.
Based on these data it may be hypothesized that activation of
both clusters by chromosomal rearrangements might be not
restricted to thyroid tumors. Balanced translocations involving
19q13.4 have also been described in mesenchymal hamartoma of
Table 2. Statistical analysis of the qRT-PCR data.
19q translocation without 19q translocation microRNA p-value d.f. t
Adenoma normal thyroid and adenoma mir371-3p 0.005355 4.48 5.0446
mir372 2.232e-06 10.996 8.9445
mir373 0.006122 8.522 3.6176
mir520c 1.722e-09 10.977 17.9765
Adenoma adenoma mir371-3p 0.004623 5.203 4.745
mir372 0.0001681 7.043 7.2279
mir373 0.01428 7.9 3.128
mir520c 4.312e-08 7.978 19.941
Adenoma normal thyroid mir371-3p 0.005471 4.159 5.2956
mir372 0.008832 2.826 6.5061
mir373 0.02236 4.122 3.5632
mir520c 0.003133 2.573 10.9875
adenoma cell line adenoma cell line mir371-3p 0.004041 4.446 5.4488
mir372 0.1121 2.4893 2.344
mir373 0.08229 2.311 2.9573
mir520c 0.001659 4.029 7.4811
Statistical analysis (t-test, two-tailed) of the expression of miRNAs from the cluster C19MC and miR-371-3 in tissues or cell lines containing 19q13 rearrangements
compared to normal thyroid tissue and/or adenomas without 19q13 rearrangements. The data were obtained using statistical software R (www.r-project.org). (d.f.=
degrees of freedom, t= Student’s t-value)
doi:10.1371/journal.pone.0009485.t002
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Of note, quite recently, genomic amplifications including the
C19MC cluster have been detected by array CGH and FISH as
recurrent genomic imbalances in an aggressive subgroup in
primitive neuroectodermal brain tumors. Functional studies
implicated two miRNAs of the cluster i.e. miR-517c and 520 g
as oncogenes causally linked to the development of the disease
[21]. More generally, breaks of chromosomal band 19q13 have
been reported in a variety of human neoplasms. Furthermore,
according to the CancerChromosomes/Mitelman database
(NCBI) chromosomal band 19q13 belongs to the areas most
frequently targeted by chromosomal aberrations at all in the
Figure 4. Fluorescence in situ hybridization (FISH) with dual-color, break-apart rearrangement probe (tbpc19). (A)–(E) I-FISH showing
19q13 rearrangements detected using touch-preparations of five thyroid adenomas (A: S801, B: S814, C: S842, D: S846, E: S849) indicated by
separated green (39-tbpc19) and red signals (59-tbpc19); (F) Metaphase of case S842 with a t(1;19)(q32;q13) after FISH with tbpc19. The 19q13
rearrangement is indicated also by separated signals on der(1) and der(19).
doi:10.1371/journal.pone.0009485.g004
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of these do also target either of the two or both miRNA clusters
investigated herein. However, there is ample evidence that within
the thyroid epithelium the clonal re-expression of two important
‘‘embryonic’’ miRNA clusters with thousands of potential targets is
causally linked to the development of a large subgroup of thyroid
adenomas. Effects of individual of these miRNAs with single
targets have been associated with human tumors but mechanis-
tically the effects observed are more likely to result from global
changes of gene expression than from the de-regulation of single
targets of the corresponding miRNAs.
Methods
Ethics Statement
The use of human thyroid tumors for this study (including the
preparation of the cell lines S270.2 and S290.1) was approved by
the local medical ethics committee and followed the guidelines of
the declaration of Helsinki. Only samples that were initially taken
for diagnostic purposes were secondarily used for the present
study. Because the samples were de-identified and were considered
as samples normally discarded, the committee felt that there was
no specific patient consent necessary.
Tissue and Cell Lines
All samples were obtained from patients undergoing thyroid
resection in the Department of General and Visceral Surgery of
the St. Joseph Stift, Bremen (Germany). One piece of each tumor
was stored in Hank’s solution for cell culture and a second piece
was stored in liquid nitrogen for gene expression studies. The cell
lines were derived from thyroid adenoma cells as reported
previously [22]. Archival RNAs from fetal, placental and testicular
tissue were used as controls.
Cell Culture and Cytogenetic Analyses
Tissue digestion, cultivation of primary cell lines, and
cytogenetic analyses were performed according to previously
described methods [2,23]. Before digestion, each sample was
touched onto slides to get samples for FISH screening.
Isolation of RNA, Reverse Transcription and Real-Time
PCR (qRT-PCR) Quantification
Total RNA was extracted from tissue as well as from
immortalized cell lines using TRIzol (Invitrogen, Karlsruhe,
Germany) reagent, or mirVana (Ambion, Woodward, USA)
Figure 5. Partial karyotype of cell line S40.2. Partial G-banded
karyotype showing chromosome 1 and 19 as well as their derivatives
resulting from t(1;19)(p35.2;q13.4).
doi:10.1371/journal.pone.0009485.g005
Figure 6. Delineation of PUM1 breakpoint by metaphase FISH. Part
of metaphase of cell line S40.2 after FISH with two overlapping BAC clones
RP11-201O14 (green) and RP11-1136E4 (red) both spanning the whole
genomic sequence of PUM1 in 1p35.2. The breakpoint in 1p35.2 is located
within PUM1 indicated by a separation of RP11-201O14 and RP11-1136E4.
Because of weak signals of RP11-1136E4 remaining on the der(1) the
breakpoint is located within RP11-1136E4 distal to RP11-201O14.
doi:10.1371/journal.pone.0009485.g006
Figure 7. Genomic organization of the fusion gene on the derivative chromosome 1 resulting from a translocation
t(1;19)(p35.2;13.4) in cell line S40.2. Detailed schematic overview illustrating the origin of the fusion transcripts PUM1-FUS-19q-I (Genbank
Accession number GQ334687) and PUM1-FUS-19q-II (Genbank Accession number GQ334688) identified in cell line S40.2. The genomic region of
PUM1 in 1p35.2 (horizontal gray bar) fuses after exon 10 of PUM1 (exons: vertical light gray bars) to the genomic region of C19MC in 19q13.4
(horizontal red bar). The two vertical yellow bars indicate 39-sequences located after exon 1–10 of PUM1 in PUM1-FUS-19q-I and PUM1-FUS-19q-II,
respectively, both originating from alternative splicing. The fusion transcripts were detected either by 39-RACE-PCR (PUM1-FUS-19q-I) or RT-PCR
(PUM1-FUS-19q-II) experiments. The quantified miRNAs have been highlighted by their names.
doi:10.1371/journal.pone.0009485.g007
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miRNA (miR-371-3p, miR-372, miR-373 and miR-520c) and
RNU6B (RNA, U6 small nuclear 2; internal control for relative
quantification)-specific cDNA were generated from 10 ng of total
RNA using the TaqMan microRNA RT Kit and the gene-specific
RT primers from the TaqMan microRNA Assays (Applied
Biosystems, Foster City, CA, USA) according to the manufactur-
er’s instructions. The reactions were incubated in a thermal cycler
for 30 min at 16uC, 30 min at 42uC, 5 min at 85uC and then
stored at 4uC. All reverse transcriptions included no-template
controls and minus RT controls (–RT).
Real-time PCR was performed using an Applied Biosystems
7300 Fast Real Time PCR system with miRNA and RNU6B-
specific probes and TaqMan Universal PCR Master Mix (Applied
Biosystems, Foster City, CA, USA). The reactions were incubated
in 96-well plates at 95uC for 10 min followed by 40 cycles of 15 s
at 95uC and one min at 60uC. All reactions were run in triplicate.
Relative quantification (RQ) was calculated using Applied
Biosystems SDS software based on the RQ=2_DDCt 2(–Delta
Delta C(T)) method [24]. Ct data were normalized to the internal
control, RNU6B [25].
Detection of Fusion Transcripts via 39RACE-PCR
39RACE-PCR was performed on cell line S40.2. Total RNA
was isolated using RNeasy Mini Kit (Qiagen, Hilden,
Germany). cDNA syntheses were carried out with slight
modifications following the instructions for the M-MLV
reverse transcriptase using oligo(dT) primer as anchor primer
(Invitrogen, Karlsruhe, Germany). 39RACE-PCRs and Nested
39RACE-PCRs were performed as described in the Gene
Racer Kit (Invitrogen, Karlsruhe, Germany) adjusted to the
conditions for GoTaq Flexi DNA Polymerase (Promega,
Mannheim, Germany). Southern Blots were carried out as
mentioned by Fehr et al. [26] with PUM1-specific probe
labelled with digoxigenin-11-dUTP (Roche Diagnostics, Penz-
berg, Germany). Fragments of interest were excised and
extracted with the QIAquick Gel Extraction Kit (Qiagen,
Hilden, Germany) and were then cloned into the pGEM-T
Easy Vector (Promega, Mannheim, Germany). The plasmid
DNA from the clones of interest was isolated via QIAprep Spin
Miniprep Kit (Qiagen, Hilden, Germany) and sequenced by
Eurofins MWG, Ebersberg, Germany.
Detection of Fusion Transcripts via RT-PCR
With the program polyadq [27], the possible PolyA-site of the
C19MC-cluster was detected. Nearby a primer was designed
which was later used together with a PUM1-specific primer. Total
RNA of S40.2 isolated via TRIzol reagent (Invitrogen, Karlsruhe,
Germany) was used for cDNA syntheses as previously described.
PCR was done with the GoTaq Flexi DNA-Polymerase (Promega,
Mannheim, Germany) followed by a semi-nested PCR. Fragments
of interest were excised and extracted as described above and
sequenced by Eurofins MWG, Ebersberg, Germany.
Validation of the Fusion Transcript
To confirme the former results, different primers localized
within the fusion transcript were utilized. The PCRs were carried
out as described above. Fragments of the expected size were
excised, extracted and sequenced (see above).
RT-PCR
miRNA-specific-primers for miR-512-5p, miR-517a and miR-
519a were designed, as described by Chen et al. [28]. cDNA was
generated from 1 mg total RNA according to Chen et al. [28] with
small modifications in stem-loop-primer concentration (5 nM), as
well as the PCR-reactions that were modified in annealing-
temperature (68uC) and -duration (10 s). The RT-PCR was
performed with GoTaq Flexi DNA-Polymerase (Promega GmbH,
Mannheim, Germany). Elongation was run at 72uC for 15 s.
Primers
See Table 3.
Figure 8. Cloning of fusion transcripts PUM1-FUS-19q-I and
PUM1-FUS-19q-II. Fusion transcripts resulting from the t(1;19) in cell
line S40.2 were detected by RT-PCR and analyzed by gel electropho-
resis. M= Marker DNA (1 kb+, Fermentas). S40.2= Thyroid adenoma
cell line S40.2. The arrows point to the corresponding bands that were
excised. Isolated DNA was sequenced and analyzed. Weak bands above
may represent splice variants. A) Transcript PUM1-FUS-19q-I generated
with primers Ex9_up and 19_2. B) Transcript PUM1-FUS-19q-II
generated with primers Ex9_up and 500_Cluster_polyA_I.
doi:10.1371/journal.pone.0009485.g008
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Interphase FISH (I-FISH) analyses were performed on touch-
preparations of thyroid tumors. For detection of 19q13.4
rearrangements a dual-color, break-apart rearrangement probe
( P a n P a t h ,B u d e l ,N e t h e r l a n d s )r eferred to as tbpc19 (thyroid
breakpoint cluster 19q13) was used. The rearrangement probe is
a mixture of two probes located distal (39-tbpc19; labeled by
Alexa Fluor 488) and proximal (59-tbpc19; labeled by Alexa-
Figure 9. Sequence analysis of the genomic structure of PUM1-FUS-19q. Genomic organization of part of FUS-19q. Blue double arrows
indicate exon 11 of PUM1-FUS-19q. The green arrow marks the final part of the fusion protein. The underlying ruler shows the final amino acid
sequence. The bases ag (red) correspond to the intron 10 (chromosome 19 part) splice site. Solid blue double arrows indicate the polypyrimidine tract
(PPT). A) Chromosome 19 derived part of the genomic sequence of PUM1-FUS-19q-I. B) Chromosome 19 derived part of the genomic sequence of
PUM1-FUS-19q-II. Black line indicates the Alu–repeat. Site of Primer 500-Cluster_PolyA_I is shown by a black arrow. Red line (PS) and red box (P)
indicates predicted poly (A) signals. C) Intron 10 splice sites of the two PUM1-FUS-19q variants.
doi:10.1371/journal.pone.0009485.g009
miRNA-Activation in Thyroid
PLoS ONE | www.plosone.org 9 March 2010 | Volume 5 | Issue 3 | e9485Fluor 555), respectively, of the common breakpoint-cluster
region in 19q13.4 in benign thyroid lesions. 10 mlo ft h eb r e a k -
apart probe were used per slide. Co-denaturation was
performed on a Mastercycler gradient (Eppendorf, Hamburg,
Germany) for 3 min at 80uC followed by overnight hybridiza-
tion in a humidified chamber at 37uC. Post-hybridization was
performed at 61uC for 5 min in 0.1xSSC. Interphase nuclei
were counterstained with DAPI (0.75 mg/ml). Slides were
examined with a Axioskop 2 plus fluorescence microscope (Carl
Zeiss, Go ¨ttingen, Germany). Images were captured with an
AxioCam MRm digital camera and were edited with AxioVi-
sion (Carl Zeiss, Go ¨ttingen, Germany). For each case 200 non-
overlapping nuclei were scored. Co-localized signals (green/red)
indicate a non-rearranged breakpoint region, whereas separated
green and red signals indicate a rearrangement of the
chromosomal region 19q13.4. Metaphase-FISH with tbpc-19
on case S842 was performed as described above for I-FISH on
touch-preparations. Treatment of metaphases was carried out as
described by Kievits et al. [29].
For determination of the breakpoint on chromosome 1 FISH
was performed on metaphase preparations of the cell line S40.2.
As probes two overlapping clones RP11-1136E4 (Genbank
Accession number AQ707626 and AQ733864) and RP11-
201O14 (Genbank Accession number AL356320.8) (imaGenes,
Berlin, Germany) both spanning the whole genomic sequence of
PUM1 were used. DNA was isolated using Qiagen Plasmid Midi
Kit (Qiagen, Hilden, Germany). 1 mg of isolated plasmid DNA
was labeled by nick translation (Roche, Mannheim, Germany)
either with digoxigenin-11-dUTP (RP11-201O14) or biotin-16-
dUTP (RP11-1136E4). Treatment of metaphases and subse-
quent FISH experiments were carried out as described
previously by Kievits et al. [29] with exception for co-
denaturation and post-hybridization which were performed as
described above.
Statistical Analysis
Results are presented as the mean 6 standard error (SE).
Statistical comparisons were performed by a nonpaired Student’s t
-test. A p-value of less than 0.05 was considered significant.
Data Deposition
The complete fusion transcript sequences has been deposited
in GenBank, PUM1-FUS-19q-I (Genbank Accession number
Table 3. Used Primers.
PUM 1
Primer (Exon) sequence (59 -39) company
Ex1_Up (Exon 2) CCCTCAAGAACCAGCTAATCCCAACA Invitrogen
Ex3_Up (Exon 4) TTCCTGGGTGATCAATGGCGAGA Invitrogen
Ex4_Up (Exon 5) TCCCCGGGCGATTCCTGTCT Invitrogen
Ex5_Lo (Exon 6) TCCATCACATCACCCTCCTCCTTCAA Invitrogen
Ex7_Up (Exon 8) ACCTAATGCGCTTGCTGTCCA Invitrogen
Ex8_Up (Exon 9) GCTCCCGCTGCGTTTGTCC Invitrogen
Ex9_Up (Exon 10) CAACAGACCACCCCACAGGCTCAG Invitrogen
Ex11_Lo (Exon 12) ATTTCTCGCGCCTGCATTCACTAC Invitrogen
Ex12_Up (Exon 13) CCAGTTCTTTCTACGGCAACAACTCTCTG Invitrogen
Ex14_Up (Exon 15) AACTGCGGGAGATTGCTGGACATA Invitrogen
Ex14_Lo (Exon 15) CCATTATATGTCCAGCAATCTCCCGC Invitrogen
Ex17_Lo (Exon 18) CGATGATAAATTGCAAAGACTGGGGC Invitrogen
Ex19_Up (Exon 20) TGAGGATAAAAGCAAAATTGTAGCAGAA Invitrogen
Ex20_Up (Exon 21) GGAGCCAGGCCAGCGGAAGATC Invitrogen
Ex21_Lo (Exon 22) GCCAGTGAGGTCAGCGGGAATG Invitrogen
39UTR_Lo (Exon 22) AATCCAGTAGGCAGTAAACAATCACACC Invitrogen
59UTR_Up (Exon 1) AGAGAGAAGATCGGGGGGCTGAAAT Invitrogen
cDNA/39RACE
AP2 AAGGATCCGTCGACATC(T)17 Invitrogen
Oligo dT GCTGTCAACGATACGCTACGTAACGGC Invitrogen
ATGACAGTG(T)24
UAP2 CTACTACTACTAAAGGATCCGTCGACATC Invitrogen
Gene Racer 39 GCTGTCAACGATACGCTACGTAACG Invitrogen
Gene Racer 39Nested CGCTACGTAACGGCATGACAGTG Invitrogen
GAPDH2_Up GTGAAGGTCGGAGTCAACG Invitrogen
GAPDH5_Lo AGGAGGCATTGCTGATGAT Invitrogen
Chromosome 19 miRNA cluster C19MC
19_1 GGCTGCCCAGGGAGTTGCT Invitrogen
19_2 GCAGAAGCTCCCAGCCAGATCTT Invitrogen
19_3 CTAGGGTTCGCTGTCCTCACACTGC Invitrogen
500-Cluster_PolyA_I CAACCGTTGGGGATTACAAAATAGA Invitrogen
Stem-loop-Primers
miR-371-5p a sl GTCGTATCCAGTGCAGGGTCCGAGGTAT Invitrogen
TCGCACTGGATACGACACACTC
miR-371-5p sl GTCGTATCCAGTGCAGGGTCCGAGGTAT Invitrogen
TCGCACTGGATACGACAGTGCC
miR-372 sl GTCGTATCCAGTGCAGGGTCCGAGG Invitrogen
TATTCGCACTGGATACGACACGCTC
miR-373 sl GTCGTATCCAGTGCAGGGTCCGAGGTAT Invitrogen
TCGCACTGGATACGACACACCC
miR-512-5p sl GTCGTATCCAGTGCAGGGTCCGAGG Invitrogen
TATTCGCACTGGATACGACGAAAGT
miR-517a sl GTCGTATCCAGTGCAGGGTCCGAGG Operon
TATTCGCACTGGATACGACACACTC
miR-520c-3p sl GTCGTATCCAGTGCAGGGTCCGAGGTAT Invitrogen
TCGCACTGGATACGACACCCTC
miR-520c-5p sl GTCGTATCCAGTGCAGGGTCCGAGGTAT Invitrogen
TCGCACTGGATACGACCAGAAA
Table 3. Cont.
Forward and Reverse Primers (PCR)
miR-371-3p fw ACCGCTAAGTGCCGCCATCTTTTG Invitrogen
miR-371-5p fw GCCGCCACTCAAACTGTGGGG Invitrogen
miR-372 fw GGTCATAAAGTGCTGCGACATTTG Invitrogen
miR-373 fw TTCATGAAGTGCTTCGATTTTGG Invitrogen
miR-512-5p fw AGTCTACACTCAGCCTTGAGGGCA Invitrogen
miR-517a fw CGGCGGATCGTGCATCCCTTTA Operon
miR-519a fw CCGGCTAAAGTGCATCCTTTTAG Invitrogen
miR-520c-3p fw GCCGCCAAAGTGCTTCCTTTTAG Invitrogen
miR-520c-5p fw ACCGCTCTCTAGAGGGAAGCAC Invitrogen
Reverse Primer GTGCAGGGTCCGAGGT Operon
Primer sequences for PCR and cDNA synthesis.
doi:10.1371/journal.pone.0009485.t003
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GQ334688).
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